Insights from 2023 ASCO® Annual Meeting


 

ASCO® 2023 Insights: "FGFR3 Alterations in Phase III PROOF 302 Trial: Infigratinib (BGJ398) as Adjuvant Therapy in Patients With Invasive Urothelial Carcinoma"

181 views
June 6, 2023
Comments 0
Login to view comments. Click here to Login